@article{f92f8624d72d45b384c4327bc627983e,
title = "2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia",
keywords = "Adult, Advisory Committees, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal/therapeutic use, Anticholesteremic Agents/therapeutic use, Coronary Artery Disease/drug therapy, Female, Humans, Hyperlipoproteinemia Type II/drug therapy, Male, Middle Aged, Proprotein Convertase 9/antagonists \& inhibitors",
author = "Ulf Landmesser and Chapman, \{M. John\} and Stock, \{Jane K\} and Pierre Amarenco and Belch, \{Jill J F\} and Jan Bor{\'e}n and Michel Farnier and Ference, \{Brian A\} and Stephan Gielen and Ian Graham and Grobbee, \{Diederick E\} and Hovingh, \{G. Kees\} and L{\"u}scher, \{Thomas Felix\} and Piepoli, \{Massimo F.\} and Ray, \{Kausik K.\} and Stroes, \{Erik S G\} and Olov Wiklund and Stephan Windecker and Zamorano, \{Jose Luis\} and Fausto Pinto and Lale Tokg{\"o}zoglu and Bax, \{Jeroen J.\} and Catapano, \{Alberico L.\}",
note = "Funding Information: Funding for travel to participate in Task Force meetings was provided by the European Atherosclerosis Society.",
year = "2018",
month = apr,
day = "7",
doi = "10.1093/eurheartj/ehx549",
language = "English",
volume = "39",
pages = "1131--1143",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "14",
}